Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-50633 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- IBSP Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- The antibody detects endogenous levels of total IBSP protein.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1.4 mg/mL
- Storage
- -20°C
Submitted references Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer.
Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y, Wu SY, Zhao D, Tyagi A, Deshpande RP, Pei X, Ruiz MG, Takahashi H, Tsuzuki S, Kimura T, Mo YY, Shiozawa Y, Singh R, Watabe K
Nature communications 2021 Aug 31;12(1):5196
Nature communications 2021 Aug 31;12(1):5196
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of IBSP was performed by loading (from left to right): Hela, K562 and hepG2 cell lysates (40µg) on to a 8% SDS-PAGE gel. Proteins were transferred to a membrane and the membrane was probed with a IBSP antibody (Product # PA5-50633) at a 1/350 dilution for 10 seconds, followed by a secondary antibody at 1/8000.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 Bone-metastatic ER + breast cancer cells secrete miR-19a and IBSP. a EVs were prepared from the conditioned medium of bone-metastatic cell line MCF7BoM2 and the parental cell line MCF7, followed by extraction of RNA. They were then subjected to miRNA profiling by GeneAtlas miRNA Array. Using the criteria of FDR < 0.05 and Fold change > 1.3, 156 miRNAs were selected for further study. These miRNAs were then examined whether they are secreted in the blood of ER + patients using the cohort data set (GSE41922) of the circulating microRNA profiles between 23 ER + breast cancer (BC) patients and 22 healthy donors (Normal). Three miRNAs (miR-19a. miR-133b, miR-576-5p), were found to be significantly upregulated (FDR < 0.05 and logFC > 0.5) in the blood of breast cancer patients. BoM, bone metastatic. b Kaplan-Meier analysis of miR-19a was performed between breast cancer patients with low miR-19a and high miR-19a expression using GSE22220. c RNA from bone-met(metastatic) lesions ( n = 6), primary tumors ( n = 6), lung and brain lesions ( n = 6) of ER + breast cancer patients, and normal bones ( n = 4) was extracted and miR-19a expression was examined by Taqman-PCR. A two-sided student's t -test was performed (Primary vs Bone-met, p = 0.0047; Other-met vs Bone-met, p = 0.0249; Normal Bone vs Bone-met, p = 0.0059). Data are presented as mean values +- SEM. d The expression of miR-19a in parental cell lines (MCF7, T47D, and MDA-MB-231) and bone-tropic cell lines (MCF7BoM2, T47DBo
